Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 9/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9026943 | 0.84 | HCAR2 (0.72) | HCAR2NPC1RAB9ATAAR1SLC6A3 | |
| SCHEMBL19382697 | 0.82 | HCAR2 (0.70) | HCAR2NPC1RAB9ATAAR1SLC6A3 | |
| SCHEMBL28251799 | 0.82 | HCAR2 (0.70) | HCAR2NPC1RAB9ATAAR1SLC6A3 | |
| SCHEMBL28628018 | 0.80 | HCAR2 (0.67) | HCAR2 | |
| SCHEMBL11203508 | 0.79 | HCAR2 (0.66) | HCAR2NPC1RAB9ATAAR1SLC6A3 | |
| SCHEMBL16619585 | 0.79 | HCAR2 (0.66) | HCAR2NPC1RAB9ATAAR1SLC6A3 | |
| SCHEMBL11411101 | 0.79 | HCAR2 (0.65) | HCAR2 | |
| SCHEMBL3131871 | 0.78 | HCAR2 (1.00) | HCAR2 | |
| SCHEMBL28835744 | 0.78 | HCAR2 (0.65) | HCAR2 | |
| SCHEMBL17224976 | 0.78 | HCAR2 (0.70) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12221420-B2 | Process for the preparation of substituted pyrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2025-02-11 | — | — | US | claimed |
| EP-3997085-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2022-05-18 | — | — | EP | claimed |
| US-20220127236-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-04-28 | — | — | US | claimed |
| CN-114144412-A | Process for preparing substituted pyrazole derivatives | 豪夫迈·罗氏有限公司 | 2022-03-04 | — | — | CN | claimed |
| WO-2021005137-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-01-14 | — | — | WO | claimed |
| CN-115916770-B | H4 antagonist compounds | 奈克斯拉制药英国有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-12221420-B2 | Process for the preparation of substituted pyrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-12221420-B2 | Process for the preparation of substituted pyrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20230167094-A1 | H4 ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | US | disclosed |
| CN-115916770-A | H4 antagonist compounds | 赫普泰雅治疗有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4139300-A1 | H4 ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2023-03-01 | — | — | EP | disclosed |
| CN-114874143-A | Regulator containing pyrazole derivatives, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-20190010148-A1 | MORPHOLINE DERIVATIVE | HOFFMANN-LA ROCHE INC. (US) | 2019-01-10 | — | — | US | disclosed |
| WO-2017157873-A1 | 5-ETHYL-4-METHYL-PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING ACTIVITY AS AGONIST OF TAAR | F. HOFFMANN-LA ROCHE AG (CH) | 2017-09-21 | — | — | WO | disclosed |
| CN-101765596-B | Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER IP GMBH | 2015-04-29 | — | — | CN | disclosed |
| US-8796253-B2 | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-05 | — | — | US | disclosed |
| US-20100249085-A1 | HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-30 | — | — | US | disclosed |
| CN-101765596-A | Inhibitors of hypoxia inducible factor (HIF) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER HEALTHCARE AG | 2010-06-30 | — | — | CN | disclosed |
| EP-0725783-A1 | 2-(PYRAZOL-3-YL)CARBAPENEM DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995011905-A1 | 2-(PYRAZOL-3-YL)CARBAPENEM DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221420-B2 | Process for the preparation of substituted pyrazole derivatives | CYP3A5, CYP3A4, CYP3A7 | HCAR2 2112/4885NPC1 1527/4885RAB9A 650/4885 |
| US-20100249085-A1 | HETEROARYL SUBSTITUTED PYRAZOLE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | FLT4, VEGFA, MKI67 | HCAR2 560/4885NPC1 1028/4885RAB9A 1563/4885 |
| US-20190010148-A1 | MORPHOLINE DERIVATIVE | TAAR1, TAAR5, TACR1 | HCAR2 47/4885NPC1 1131/4885RAB9A 1491/4885 |
| US-20230167094-A1 | H4 ANTAGONIST COMPOUNDS | HRH4, HRH3, HRH2 | HCAR2 14/4885NPC1 1320/4885RAB9A 2672/4885 |
| US-20220127236-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRAZOLE DERIVATIVES | CYP3A5, CYP3A4, CYP3A7 | HCAR2 2112/4885NPC1 1527/4885RAB9A 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.